<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487654</url>
  </required_header>
  <id_info>
    <org_study_id>13SM0713</org_study_id>
    <nct_id>NCT02487654</nct_id>
  </id_info>
  <brief_title>Ectopy Triggering Ganglionated Plexus Ablation to Prevent Atrial Fibrillation</brief_title>
  <acronym>GANGLIA-AF</acronym>
  <official_title>Ectopy Triggering Ganglionated Plexus Ablation to Prevent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is a common heart rhythm disorder which can significantly affect a
      patient's quality of life and cause strokes. Abnormal electrical activity from the pulmonary
      veins are thought to be the most common cause of this condition. Current ablative strategy in
      drug refractory AF is pulmonary vein isolation (PVI), where the pulmonary veins are
      electrically isolated from the body of the left atrium. However, success rate of this
      procedure remain ~50-70% for a single procedure despite advances in mapping and ablation
      techniques.

      Ganglionated plexuses (GP) are dense clusters of nerves in the atria that are implicated in
      AF. Endocardial high frequency stimulation (HFS) delivered within the local atrial refractory
      period can trigger ectopy and AF from specific GP sites (ET-GP). The aim of this study was to
      understand the role of ET-GP ablation in the treatment of AF by comparing two different
      strategies:

        1. Pulmonary vein isolation alone

        2. GP ablation alone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-centre study recruiting patients with paroxysmal AF indicated
      for AF ablation.

      180 patients will be recruited. Patients are randomised to either GP ablation alone or to
      PVI. All antiarrhythmics are stopped for at least 48 hours prior to their procedures.

      All have general anaesthesia and CARTO system (Biosense Webster, inc.) are used for 3D
      electroanatomical mapping of the left atrium.

      Patients randomised to GP ablation will have high frequency mapping performed within the
      atrial refractory period to identify ectopy or AF triggering GP (ET-GP) sites in the left
      atrium. Patients in this group will only have GP ablation and will not have pulmonary veins
      isolated.

      The primary endpoint is any documented atrial arrhythmia 30 seconds or more after a 3 month
      blanking period. This will be assessed for up to 12 months post-procedure, using 48hr Holter
      monitors at 3, 6, 9 and 12 month intervals.

      Secondary endpoints include mortality, major complications and redo procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Documented recurrent atrial arrhythmia lasting 30 seconds or more after a blanking period of 3 months.</measure>
    <time_frame>3 to 12 months post-ablation.</time_frame>
    <description>Outcome measure will be assessed up to 12 months of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major complications, mortality and redo procedures</measure>
    <time_frame>3 to 12 months post-ablation.</time_frame>
    <description>Major complications include significant bleed requiring transfusions, pericardiocentesis, stroke.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganglionated plexus ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation</intervention_name>
    <description>Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.</description>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <other_name>PVI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ganglionated plexus ablation</intervention_name>
    <description>Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium</description>
    <arm_group_label>Ganglionated plexus ablation</arm_group_label>
    <other_name>GP ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females eighteen (18) to eighty five (85) years old

          -  Paroxysmal atrial fibrillation

          -  Suitable candidate for catheter ablation

          -  Signed informed consent

        Exclusion Criteria:

          -  Contraindication to catheter ablation

          -  Presence of a cardiac thrombus

          -  valvular disease that is grade moderate or greater

          -  Any form of cardiomyopathy

          -  On amiodarone therapy

          -  Severe cerebrovascular disease

          -  Active gastrointestinal bleeding

          -  Renal failure (on dialysis or at risk of requiring dialysis)

          -  Active infection or fever

          -  Life expectancy shorter than the duration of the trial

          -  Allergy to contrast

          -  Intractable heart failure (NYHA Class IV)

          -  Bleeding or clotting disorders or inability to receive heparin

          -  Serum Creatinine &gt;200umol/L

          -  Uncontrolled diabetes (HbA1c ≥73mmol/mol or HbA1c ≤64mmol/mol and Fasting Blood
             Glucose ≥9.2mmol/L)

          -  Malignancy needing therapy

          -  Pregnancy or women of childbearing potential not using a highly effective method of
             contraception

          -  Patients in current research or have recently been involved in any research prior to
             recruitment will not be included in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prapa Kanagaratnam, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College NHS Healthcare Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-young Kim, MBChB</last_name>
    <phone>+447884438572</phone>
    <email>min-young.kim@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prapa Kanagaratnam, PhD</last_name>
    <phone>02033126666</phone>
    <email>p.kanagaratnam@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afzal Sohaib</last_name>
      <email>afzal.sohaib1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Afzal Sohaib, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Hunter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Tomlinson</last_name>
      <email>david.tomlinson1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>David Tomlinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal atrial fibrillation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>Ganglionated plexus</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Pulmonary vein ectopy</keyword>
  <keyword>High frequency stimulation</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>Ganglionated plexi</keyword>
  <keyword>atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

